Compare BGSI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | ANIP |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2025 | 1999 |
| Metric | BGSI | ANIP |
|---|---|---|
| Price | $82.00 | $71.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | $104.70 | ★ $105.78 |
| AVG Volume (30 Days) | 24.9K | ★ 286.9K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 2.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $27.51 | $24.85 |
| Revenue Next Year | $8.35 | $10.76 |
| P/E Ratio | $231.07 | ★ $31.19 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $75.42 | $69.58 |
| 52 Week High | $183.10 | $95.57 |
| Indicator | BGSI | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 43.57 |
| Support Level | $75.42 | $69.88 |
| Resistance Level | $91.90 | $83.03 |
| Average True Range (ATR) | 2.51 | 1.93 |
| MACD | 0.78 | 0.06 |
| Stochastic Oscillator | 73.60 | 30.47 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. The Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.